Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Cingulate Inc. Market Cap
From what 2 stock analysts predict, the share price for Cingulate Inc. (CING) might increase by 1016.24% in the next year. This is based on a 12-month average estimation for CING. Price targets go from $8 to $75. The majority of stock analysts believe CING is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
About 2 Wall Street analysts have assignedCING 2 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect Cingulate Inc. to buy. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on CING. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of CING.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Naz Rahman Maxim Group | Buy | Upgrade | Nov 20, 2024 | |
| Raghuram Selvaraju HC Wainwright & Co. | Buy | $8 | Maintains | Jan 5, 2024 |
| Yale Jen Laidlaw & Co. | Hold | Downgrade | Dec 22, 2023 | |
| Naz Rahman Maxim Group | Hold | Downgrade | Dec 19, 2023 | |
| Naz Rahman Maxim Group | Hold | Downgrade | Dec 18, 2023 | |
| Raghuram Selvaraju HC Wainwright & Co. | Buy | $3.5 | Maintains | Sep 26, 2023 |
| Raghuram Selvaraju HC Wainwright & Co. | Buy | $5.5 | Initiates | Jan 17, 2023 |
| Naz Rahman Maxim Group | Buy | $3 | Initiates | Nov 22, 2022 |
| Yale Jen Laidlaw & Co. | Buy | $8.5 | Initiates | Jan 20, 2022 |
Aegis Capital | Buy | Initiates | Jan 11, 2022 |
When did it IPO
2021
Staff Count
13
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Shane J. Schaffer Pharm.D.
Market Cap
$14.2M
In 2023, CING generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that CING's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Thu, 07 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - The company plans to submit a New Drug Application (NDA) for its lead ADHD asset, CTx-1301, by mid-2025.
Why It Matters - The mid-2025 NDA submission for CTx-1301 indicates potential revenue growth and market entry in ADHD treatment, impacting stock performance and investor sentiment.
Tue, 08 Oct 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Cingulate Inc. CEO Shane J. Schaffer discussed the company's Phase 3 ADHD treatment CTx-1301 and commercialization plans on the Big Biz Show, highlighting its proprietary PTR™ technology.
Why It Matters - Cingulate's CEO discussing a Phase 3 ADHD treatment and commercialization plans signals potential growth and revenue opportunities, impacting stock performance and investor sentiment.
Thu, 12 Sep 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - The company raised $10 million in additional capital, enhancing its balance sheet.
Why It Matters - The $10 million capital raise enhances the company's financial stability, improving liquidity and potentially funding growth initiatives, which can lead to higher future returns.
Tue, 27 Aug 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Cingulate Inc. (NASDAQ: CING) will have Chairman and CEO Shane J. Schaffer participate in a live Benzinga All Access event on August 28, 2024, at 10:30 a.m. CST.
Why It Matters - Cingulate Inc.'s CEO participation in a prominent event highlights company visibility and potential investor interest, possibly impacting stock performance and market perception.
Fri, 23 Aug 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Cingulate Inc. (NASDAQ:CING) has adjourned its Special Meeting of Stockholders to allow more time for voting on proposals related to its drug delivery technology.
Why It Matters - Cingulate's adjournment of the Special Meeting may signal potential uncertainty or strategic shifts, impacting stockholder sentiment and market perceptions of the company's direction.
Fri, 16 Aug 2024
Sentiment - POSITIVE
Source - Invezz
Summary - Cingulate Inc (NASDAQ: CING) shares surged 115% following the company's acquisition of a European patent for its ADHD treatment, CTx-1301.
Why It Matters - Cingulate Inc's 115% stock surge signals strong investor confidence following the European patent grant for CTx-1301, potentially enhancing market position and revenue prospects in ADHD treatments.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
